We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
- Authors
Maddocks-Christianson, Kami; Slager, Susan L; Zent, Clive S; Reinalda, Megan; Call, Timothy G; Habermann, Thomas M; Bowen, Deborah A; Hoyer, James D; Schwager, Susan; Jelinek, Diane F; Kay, Neil E; Shanafelt, Tait D
- Abstract
Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2.7%) of 962 CLL patients during a median follow-up of 3.3 years. Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4%) compared with previously untreated patients (2%; P = 0.053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5.2%) compared with patients who had not received PNA (1.9%; P = 0.008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP-70, CD38, IgV(H) mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.
- Publication
British journal of haematology, 2007, Vol 139, Issue 3, p398
- ISSN
0007-1048
- Publication type
Journal Article
- DOI
10.1111/j.1365-2141.2007.06801.x